Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

By Ahmed Aboulenein and Maggie Fick WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...